In this accredited activity, a panel of experts in hematology/VTE and primary care discuss the challenge of diagnosing and treating VTE in a busy non-specialist setting. Through a dynamic discussion of risk stratification strategies, differential diagnosis tools and effective clinical strategies for managing patients who present with symptoms of a DVT or PE, participants will gain greater insight into questions that include, “Does my patient need to be evaluated for a VTE?”, “Should the patient go to an urgent care or emergency room?”, “Is this a clot that needs to be treated?” and “What are the appropriate dosing strategies for my patient with an acute DVT?”

In this accredited activity, a panel of experts in hematology/VTE and primary care address the critical question of the duration of anticoagulation in a patient who has experienced a DVT or PE. Faculty will outline the factors that will guide the nonspecialist in determining a patient’s risk of recurrence and identifying whether the patient should undergo anticoagulation of short- or long-term duration. Through the use of tools that consider not only the patient’s current and ongoing risk factors, but that provide guidance on which patients should receive D-dimer or thrombophilia testing, participants will increase their ability to answer questions that include, “Is my patient at risk for recurrence of their VTE?”, “Should I use a D-dimer test or test the patient for thrombophilia?” and “Once I have the test results, do I know what to do with them?”

In this accredited activity, a panel of experts in hematology/VTE and pharmacy address practical considerations in the management of patients on long-term anticoagulation for chronic VTE. Faculty will discuss drug-drug interactions, over-the-counter medications and supplements, and safe use of pain medications in these patients, as well as strategies for effective perioperative interruption of anticoagulants. Practical guidance on the diagnosis, assessment, and management of potential long-term sequelae of DVT and PE, post-thrombotic syndrome, and post-PE syndrome, will support clinicians in the safe and effective use of the direct oral anticoagulants in patients with chronic VTE.

In this accredited activity, a panel of experts in hematology/VTE and pharmacy address the specific challenges of treating DVT in special populations. Through a series of focused case studies, faculty will highlight practical guidance for the best treatment of VTE in elderly patients, patients who have renal disease or are on dialysis, obese patients, and patients who have had COVID. Special focus will be on VTE in women, including those with heavy menstrual bleeding or who are either planning to conceive, are pregnant or are breastfeeding. Interactive expert discussions of best practices for treating VTE in the most nuanced patients will answer the specific questions you have about your next challenging patient with VTE.

Following a DVT or PE, patients will often have numerous questions concerning the impact of the VTE on their lives and on the lives of their family members. In this accredited activity, a panel of experts in hematology/VTE and primary care discuss the most common questions patients have following a DVT or PE, including “Can I fly after my clot?”, “Don’t you need to look at my clot to make sure it hasn’t moved or changed?”, “Should you test my daughter for clots?”, “I’ve finished my anticoagulant, can I go back on my previous birth control now?”, and many more.

In this accredited activity, a panel of experts in hematology/VTE and primary care debate and discuss the most appropriate approaches to a series of complex and challenging clinical scenarios, in which treatment of the patient with VTE can be highly nuanced. Participating in this activity will provide primary care clinicians with key knowledge and strategies for identifying treatment for a superficial vein thrombosis (SVT) based on size and location of the clot, as well as for navigating the challenges of long-distance travel in patients with a VTE. Panel members will also provide guidance for managing DVT prophylaxis in patients who require either major or minor orthopedic surgery; for treating patients who develop an upper extremity VTE from a PICC line insertion; and for being an active member of the multidisciplinary treatment team in patients with VTE and active cancer.

This activity, the first in a two-part series, focuses on the effects of obesity on VTE and anticoagulation therapy. Follow along with the faculty as they clarify the relationship between obesity and VTE and outline strategies for tailoring anticoagulation therapy based on body mass index (BMI) and other relevant factors. A case study is included to help demonstrate the challenges of – and solutions to – anticoagulation therapy in this patient population.

This activity, the second in a two-part series, explores anticoagulation treatment strategies in special patient groups, including patients with heavy menses, renal issues, or a history of bariatric surgery. This activity is designed to equip its participants with strategies for ensuring optimal anticoagulation in a variety of situations in patients both with and without obesity.

Join Dr. Witt as he explains how to optimize DOAC pharmacokinetics in patients with obesity. Topics include hemostasis, the impact of obesity on clot formation, and the effects of obesity on DOAC absorption, distribution, metabolism, and excretion.

This activity is designed to educate clinicians on how to reduce care disparities and health outcomes for Black Americans in rural Mississippi with a venous thromboembolism (VTE) diagnosis, as they make the transition from a Critical Access Hospital (CAH) back into their own communities on oral anticoagulants.

This activity was previously presented as a live webinar with Q&A during May 2021. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.5 contact hours of credit and may not re-submit for credit previously awarded.